Shots:

• Pharmapark to get exclusive rights to commercialize the therapy with a status of a local product & will be responsible for filing the report in Russia and other CIS countries
• The agreement will utilize Pharmapark’s sales and marketing capabilities for the ustekinumab biosimilar program in Russia & other CIS countries. Bio-Thera will lead the development- and commercial supply of BAT2206 out of its manufacturing facilities in Guangzhou- China
• Bio-Thera’s BAT2206 has completed a P-I study and is currently being evaluated in a P-III clinical study including patients from China- Russia- and other countries & plans to file for regulatory approval with the NMPA- EMA & FDA

  | Ref: Businesswire | Image: Businesswire